Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
Lorenzo BertaniMatteo FornaiMarco ForniliLuca AntonioliLaura BenvenutiGherardo TapeteGiovanni Baiano SvizzeroLinda CeccarelliMaria Gloria MumoloLaura BagliettoNicola de BortoliMassimo BelliniSantino MarchiFrancesco CostaCorrado BlandizziPublished in: Alimentary pharmacology & therapeutics (2020)
These results suggest that oncostatin M can predict the outcome of infliximab treatment. Compared with faecal calprotectin, the predictive capability of oncostatin M was appreciable at baseline, thus indicating oncostatin M as a promising biomarker for driving therapeutic choices in Crohn's disease.